Overview

This trial is active, not recruiting.

Condition varicose ulcer
Treatments mist ultrasound therapy, standard care
Sponsor Cardiff and Vale University Health Board
Collaborator Celleration, Inc.
Start date August 2012
End date December 2013
Trial size 40 participants
Trial identifier NCT01671748, 12-SUR-5323

Summary

Chronic venous leg ulcers (VLUs) impact negatively on patients' quality of life. Standard treatment in the UK for patients with VLUs is compression bandaging or stockings. The MIST ultrasound system is a noncontact device which delivers low frequency ultrasound through a gentle saline mist directed at a patient's wound. This study aims to determine whether the use of the MIST device used in combination with standard treatments can improve healing of VLUs compared to UK standard practice. This will be assessed by measuring any reduction in wound size in the two groups after receiving 8 weeks of either Standard Care once a week or MIST combined with Standard Care three times a week.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
standard care
Compression bandaging, non-adherent dressing, and debridement if required.
(Experimental)
MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
mist ultrasound therapy MIST non-contact low-frequecy ultrasound device
Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
standard care
Compression bandaging, non-adherent dressing, and debridement if required.

Primary Outcomes

Measure
Wound area
time frame: Weeks 1 to 13 (weekly)

Secondary Outcomes

Measure
Health related quality of life
time frame: Week 1 (start) and week 13 (exit)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Venous leg ulcers (as diagnosed by the clinician) - Ankle Brachial Pressure Index (ABPI) >0.8 - If multiple ulcers are present treat largest ulcer only (index ulcer) with minimum distance of 1 cm between index ulcer and any other ulcer - 18 years or older - Ulcer size of 5 cm2 - 100 cm2 (with no longest length being greater than 10 cm) at randomisation point (week 5) - Mobile enough to attend clinic - Index ulcer between 6 weeks and 5 years duration prior to screening date Exclusion Criteria: - Uncontrolled diabetes (Hba1c ≥12%) as tested within the past 3 months - Index ulcer has active infection on day of inclusion requiring use or oral or IV antibiotics - Renal failure - Index ulcer has exposed tendons, ligaments, muscle, or bone - Osteomyelitis or cellulitis or gangrene in study limb - Subjects with amputation above a trans metatarsal amputation (TMA) in the study limb - Subjects with active malignancy on the study limb - Index ulcer that is of arterial disease aetiology - Females of child bearing potential who are not willing to use a method of highly effective contraception during the entire study - Planned vascular surgery, angioplasty, or thrombolysis procedures within the study period, or 6 weeks post-operatively - Planned surgical procedure during the study period for the index wound - Prior skin replacement, negative pressure therapy, ultrasound therapy applied to the index wound 2 weeks before screening - Oral or IV antibiotics within 48 hours of baseline measurements - Growth factor therapy within previous 14 days of screening date - Currently receiving or has received radiation or chemotherapy within 3 months of randomisation - Pregnant or breast feeding women - Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial - Subject's wound would require ultrasound near an electronic implant or prosthesis - Subjects lacking capacity to provide informed consent.

Additional Information

Official title Pragmatic Randomised Controlled Trial of MIST Ultrasound Therapy Compared to UK Standard Care for the Treatment of Non-healing Venous Leg Ulcers.
Principal investigator Keith G Harding, Professor
Description Venous leg ulcers (VLUs) are wounds which are often chronic and difficult to heal. VLUs affect between 1 and 3.2 people per 1000; they cause pain, reduced mobility and impact negatively on patients' quality of life (QoL). Standard treatment for patients with VLUs is the application of strong, sustained compression with bandages or stockings. This pragmatically-designed study aims to determine whether the use of a device called MIST used in combination with standard treatments can improve healing of VLUs compared to UK standard practice. It will also show whether the MIST regimen improves participants' QoL and reduces the incidence of infection. The MIST ultrasound system is a non-contact device which delivers low-frequency ultrasound through a gentle saline mist directed at a patient's wound. Patients (over 18 years old) will be invited to take part in this study if they have had a VLU for 6 weeks or more, which measures between 5 and 100 cm2, and is not infected. Participants with diabetes must show good blood glucose control, and those with underlying chronic disorders which may affect wound healing will be excluded. All study participants will receive four weeks of standard treatment once a week at a single clinic at the Wound Healing Research Unit (WHRU), University Hospital of Wales. Patients whose wounds reduce by more than 40% during this time will be withdrawn from the study. Remaining patients will be randomly allocated to either the active group or the control group to receive a further eight weeks of treatment. Participants in the active group will receive treatment with the MIST device three times a week, as well as standard care (change of compression bandage and dressings) three times a week. The control group will receive UK standard care (which is dressing and compression bandage change at least once a week). The participants' ulcers will be measured and photographed once a week, and the wound characteristics will be assessed. Changes in participants' health related QoL will be assessed using a questionnaire at the beginning and end of the trial. Wound recurrence rates 90 days after the end of the treatment will be assessed by telephoning patients.
Trial information was received from ClinicalTrials.gov and was last updated in September 2013.
Information provided to ClinicalTrials.gov by Cardiff and Vale University Health Board.